Table 4 Pathology results of the 70 patients with rectal cancer and synchronous liver metastases according to their management

N (%)

70 (100)

48 (69)

22 (31)

22 (50)

22 (50)

Rectal pT stage, n (%)

pT0

pT1

pT2

pT3

pT4

5 (7.1)

3 (4.4)

5 (7.1)

49 (70)

8 (11.4)

3 (6.3)

3 (6.3)

4 (8.2)

32 (66.7)

6 (12.5)

2 (9.1)

0

1 (4.5)

17 (77.3)

2(9.1)

2 (9.1)

0

2 (9.1)

17 (77.3)

1 (4.6)

2 (9.1)

1 (4.6)

1 (4.6)

16 (72.7)

2 (9.1)

Rectal pN stage, n (%)

pN0

pN1

pN2

23 (32.9)

32 (45.7)

15 (21.4)

15 (31.3)

21 (43.7)

12 (25)

8 (36.3)

11 (50)

3 (13.7)

11 (50)

8 (36.4)

3 (13.6)

9 (40.9)

10 (45.5)

3 (13.6)

Number of lymph nodes harvested, median ± IQR

25 (17–33)

24 (18–38)

26 (15–32)

27 (20–47)

26 (14–32)

Number of lymph nodes metastasis, median ± IQR

1 (0–4)

1 (0–4)

1 (0–2)

2 (0–4)

1 (0–2)

Rectal resection positive margin, n (%)

8 (11.4)

6 (12.5)

2 (9.1)

1 (4.6)

2 (9.1)

Number of liver metastasis, median ± IQR

2 (1–4)

2 (1–6)

2 (1–3)

3 (2–6)

5 (3–6)

Liver resection positive margin, n (%)

17 (24.3)

13 (27.1)

4 (18.1)

4 (18.2)

0

Percentage of liver metastasis necrosis, median ± IQR

50 (23–68)

50 (25–70)

45 (4–50)

40 (25–90)

25 (20–90)

Liver fibrosis, n (%)

16 (22.9)

14 (29.2)

2 (9.1)

1 (4.6)

2 (9.1)

Liver steatosis, n (%)

23 (32.9)

16 (33.3)

7 (31.8)

2 (9.1)

7 (31.8)

Capillary obstruction syndrome, n (%)

16 (22.9)

9 (18.8)

7 (31.8)

0

2 (9.1)

Largest size of liver metastasis (mm), median ± IQR

30 (18–40)

35 (18–40)

24 (15–31)

20 (10–39)

24 (16–41)

Molecular biology, n (%)

KRAS mutation

14(20)

8 (18.8)

5 (22.7)

3 (13.6)

5 (22.7)

BRAF mutation

1 (1.4)

1 (2.1)

0

0

0

Microsatellite instability (MSI)

1/55 (1.8)

1/39 (2.5)

0

1/18 (5)

0

Unknown statu of microsatellite instability

15 (21.4)

9 (18.3)

6 (27.3)

4 (18.2)

6 (27.3)